Senzo

BioAdvance Breaks Life Sciences Investing Record Year in 2022

Retrieved on: 
Wednesday, November 9, 2022
Organization, Bop TV, Infection, Senzo, FDA, FY, Mid-Atlantic (United States), Metastasis, Amniotic fluid, COVID, Health, Investment, Seed (TV series), Medtech, Therapy, CEO, Pharmaceutical industry, Renewable energy, Fine chemical

PHILADELPHIA, Nov. 9, 2022 /PRNewswire/ -- BioAdvance, a leading venture investor in therapeutics, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region, today announced a record-breaking year of investing with more than $4.7 million in eight new and several existing portfolio companies in 2022. During this highly active year, BioAdvance's investments in the eight new companies is the highest amount in 10 years, resulting from a revamped investment strategy that includes very early-stage innovators from a broad range of life sciences segments including digital health and cell therapy.

Key Points: 
  • "For more 20 years, BioAdvance has played an important role in the development of the thriving Mid-Atlantic biotechnology ecosystem," said BioAdvance Managing Director and CEO Dr. Shahram Hejazi .
  • BioAdvance invests at two stages of a company's lifecycle.
  • BioAdvance also made several follow-on investments in existing portfolio companies, including ENB Therapeutics , RightAir , Ossianix and Venatorx Pharmaceuticals .
  • BioAdvance is a $80-million early-stage life sciences fund with a focus in the mid-Atlantic region, investing in companies that have the potential to improve human health.

Senzo's Revolutionary Amplified Lateral Flow (ALF) Platform Delivers Rapid COVID-19 Test Exactly Matching PCR Results in 3rd-Party Study by the University of Sheffield

Retrieved on: 
Tuesday, May 31, 2022
PCR, Patient, Infection, ALF, Senzo, COVID-19, Technology, GLOBE, Pharmaceutical industry

"Senzo is improving the way diseases are diagnosed by making testing more efficient and available to more people, creating tangible medical and economic benefits for patients and healthcare providers," said Senzo CEO Jeremy Stackawitz.

Key Points: 
  • "Senzo is improving the way diseases are diagnosed by making testing more efficient and available to more people, creating tangible medical and economic benefits for patients and healthcare providers," said Senzo CEO Jeremy Stackawitz.
  • The following are Senzo's ALF results from the study:
    Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products.
  • Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms.
  • With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives.

Senzo Education Poll confirms the need for new, better rapid tests for COVID-19

Retrieved on: 
Tuesday, February 15, 2022
Education, Student, Patient, PCR, COVID-19 testing, Risk, COVID, Safety, ALF, Pharmaceutical industry, Animal, Senzo, COVID-19

These results continue to substantiate the importance of Senzo's mission to bring a better rapid-testing COVID-19 product to market.

Key Points: 
  • These results continue to substantiate the importance of Senzo's mission to bring a better rapid-testing COVID-19 product to market.
  • "This poll provides further evidence of the need for better rapid testing to get the world back to normal, and Senzo is poised to deliver our ALF COVID-19 test to achieve this," added Senzo CEO, Jeremy Stackawitz .
  • This further confirms Senzo's stance that current rapid testing is not where it should be in terms of accuracy.
  • Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms.